Jump to content

3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine

From Wikipedia, the free encyclopedia
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine
Legal status
Legal status
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)-N-hydroxy-N-methylpropan-2-amine
CAS Number
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15NO3
Molar mass209.245 g·mol−1
3D model (JSmol)
  • C1=C2C(=CC=C1CC(C)N(C)O)OCO2

3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine (MDHMA; FLEA) is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. MDHMA was first synthesized and assayed by Alexander Shulgin.[1] In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours.[1] He describes MDHMA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses.[1]

Legality

[edit]

United Kingdom

[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

References

[edit]
  1. ^ a b c Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
[edit]